Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China

Fig. 3

Changes in the median levels of lipids from the beginning of the study to the end of it in the modified intent-to-treat groups. Changes in lipid levels, after correcting for placebo, were shown in individuals with hypertriglyceridemia who took either IPE (4 g/day) or IPE (2 g/day) during the course of the study. ***P < 0.001. NS indicates that the difference between the groups is not statistically significant

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X